SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi Mantra
SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi Mantra FORT LAUDERDALE, Fla. – October 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII) , a
- Product
- SSi Mantra
- Milestone
- NDA submission
- Indication
- cholecystectomy (gallbladder removal)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The response indicates progress toward clearance, which could unlock U.S. market entry and revenue growth for SS Innovations.
Market read
Regulatory progress for a Nasdaq‑listed med‑tech firm; potential catalyst for stock but impact depends on final FDA decision.
What to watch
The timing of the FDA decision (Q1 2027) may delay any near‑term price move; market may already price in the response.
Background
The filing is a standard 8‑K disclosure of a regulatory response, providing the first public details of the expanded clinical and human‑factors data submitted to the FDA.
Ticker impact
SS Innovations filed an 8‑K reporting its response to the FDA's request for additional information on the SSi Mantra 510(k) submission, a new regulatory development for the company.
likely upward pressure as market prices in the prospect of FDA clearance
Regulatory progress is a material catalyst for a medical‑device firm; no new quantitative data but the filing is the first public disclosure of the response.
Market effects
May boost sentiment for the surgical‑robotics and broader med‑tech sector as FDA engagement signals regulatory momentum.
Limited to U.S. investors; the company is headquartered in India but listed in the U.S.
Modest global relevance; could influence other med‑device firms awaiting FDA clearance.
Counterpoint
If the FDA raises further concerns, the stock could face downside despite the filing.
Key entities
- companySS Innovations International, Inc.
Developer of the SSi Mantra surgical robotic system, listed on Nasdaq (SSII).
- regulatorU.S. Food and Drug Administration
Federal agency reviewing the 510(k) submission for the SSi Mantra.
